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1. Introduction
Ibopamine (3,4 di-isobutyrrylester of N-methyldopamine) at 2% concentration, when instilled
in the conjunctival sac, stimulates ocular D1-dopaminergic and α-adrenergic receptors [1,2].
It is a pro-drug of epinine (N-methyldopamine) (Figure 1). It has positive inotropic effects: it
improves cardiac function and it is effective in the treatment of congestive heart failure. The
pharmacological ocular characteristics of ibopamine are as follows:
• It increases aqueous humor production following D1-dopaminergic stimulation;
• It is a provocative test for evaluating the function of aqueous humor outflow structures;
• It can be used to treat ocular hypotension;
• It induces a noncycloplegic mydriasis (α-adrenergic action);
• It is very useful, apart from genetic testing, to detect a predisposition to ocular hypertension
and even glaucoma in relatives of glaucoma patients.
In the conjunctival sac, ibopamine is fastly hydrolysed to epinine by the esterases of the
aqueous humor and ocular tissues. This hydrolysis suggests that epinine is the active compo‐
nent of the molecule. The half-life of ibopamine in the aqueous humor is short (about 2 minutes)
and epinine formation precedes the mydriatic effect [3,4] (Figure 1). It has been proved that
after the instillation of ibopamine, only epinine can be found in the aqueous humor [3].
When hydrolysed to epinine, ibopamine stimulates the α-adrenergic and D1 dopaminergic
receptors. The mydriatic effect of ibopamine is due to the stimulation of the α-adrenergic
receptors of the dilating muscle of the pupil. Since ibopamine has no effect on the ciliary
muscle, the mydriasis is not accompanied by cycloplegia. Mydriasis can be antagonized and
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reversed by pre-treatment by α-blocking agents (such as thymoxamine and dapiprazole). Some
Randomized Clinical Trials (RCTs) show that the D1 dopaminergic activity of the drug
increases aqueous humor production and intraocular pressure (IOP) in open-angle glaucoma
(POAG) patients [5].
Ibopamine has low toxicity both at systemic and local levels. LD50 is 2056 mg/Kg, 4930 mg/Kg
and 1786 mg/Kg in mice, rats and guinea pigs respectively. Ibopamine is well tolerated without
any significant change to the haematological and behavioural parameters. 2% ibopamine eye
drops show that ibopamine is well tolerated at local level, without systemic side-effects and
tachyphylaxis phenomena. One drop of 2% ibopamine contains 1 mg of the compound, while
the oral dosage is higher than 400 mg/day. Electrophysiological assessment showed that
ibopamine is not retinotoxic at all [6].
2. Clinical use
2.1. Non-cycloplegic mydriatic activity
In binocular indirect examination of fundus oculi with scleral indentation, fluorescein and
indocyanine angiography, and in the laser treatment of retinal lesions, ibopamine can induce
a fast, short-lasting (2-3 hours) maximal mydriasis without cycloplegic effects or local a/or
systemic side-effects [7]. The mydriatic effect of ibopamine can be prolonged if repeatedly
administered (every 30 minutes). Ibopamine-induced mydriasis can be reversed by local
application of α-blockers such as thymoxamine and dapiprazole. Ibopamine can substitute
phenylephrine in association with tropicamide a/or cyclopentolate to avoid the typical
discomfort of cycloplegia mostly in adults [7]. Ibopamine eye drops is effective in inducing
pre-operative mydriasis, without effects on the cardiovascular system [7]. In the post-operative
period ibopamine can induce a fast and short-lasting mydriasis to induce pupil dilatation.
Figure 1. Dopamine →  Epinine →  Ibopamine (3,4 dyisobutyrrilester of N-methyldopamine).
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2.2. Pathophysiology of IOP
2% ibopamine eye drops increases IOP only in patients suffering from POAG. Ibopamine is
useful in different ways:
• Physiological studies on IOP;
• Evaluation of trabecular outflow pathways (pressure-dependent outflow);
• Treatment of ocular hypotony.
The instillation of ibopamine increases the IOP only in about 96% of eyes with POAG [8,9,10]
(Figures 2, 3). In normal eyes, 2% ibopamine does not significantly affect IOP, with a possible
mild hypotensive effect (1-2 mmHg) (Figure 4). The IOP, in POAG patients, increases by a
maximum value of 10-11 mmHg within 45 minutes from the instillation and lasts about 180
minutes [7,8,9,10,11,12,13,14]. To observe this effect, 2 drops of 2% ibopamine have been
instilled 5 minutes apart, and IOP was measured 45 minutes after the first instillation. The
ibopamine provocative test shows a significant correlation with the highest intraocular
pressure in the diurnal tension curve in glaucoma patients [15]. Indeed, in glaucoma patients
with early visual field defect, the ibopamine provocative test has shown better sensitivity/
specificity than the water drinking test [16]. Ibopamine test does not modify the results of
visual field tests in normal individuals [17].
Figure 2. Effect on the intraocular pressure of 2% ibopamine and 10% phenylephrine in glaucomatous patients and
in normal volunteers.
Ibopamine – A New Alpha-Adrenergic and D1-Dopaminergic Drug
http://dx.doi.org/10.5772/58380
473
Figure 3. Effect on the pupillary diameter of 2% ibopamine and 10% phenylephrine in glaucomatous patients and in
normal volunteers.
Figure 4. ibopamine induces a transient ocular hypertensive effect (mean, 8.31±2.14 mmHg) in 96% of eyes of pa‐
tients affected by POAG, whereas in healthy eyes there is a reduction of intraocular pressure (IOP) by 1 to 2 mmHg.
Several studies have been performed to assess the following issues:
Ophthalmology - Current Clinical and Research Updates474
• Identification of the responsible receptor (agonist and antagonist);
• Evaluation of the change of the aqueous humor dynamics;
• Evaluation of ibopamine effects when the outflow system was experimentally impaired.
Only the D1 agonist substances, such as fenoldopam, have the same effect as ibopamine on
IOP in POAG patients. D1 agonist drugs increase the IOP only in POAG, but never in healthy
eyes, stressing the involvement of D1 dopaminergic receptors on the mechanism stimulating
the aqueous humor production.
The hypertensive effect of ibopamine in POAG is completely counteracted by the pre-
treatment with a selective antagonist of the D1 receptors such as SCH23390. A clear receptorial
antagonism for IOP has been identified. Ocular anti-hypertensive drug, such as β-blockers and
α-agonists do not antagonize the hypertensive effects of ibopamine in POAG [14]. The partial
antagonism performed by glycerol is due to an osmotic reduction of the vitreous mass.
When there is a marked increase of aqueous humor production, due to the D1 dopaminergic
effect of ibopamine, the healthy eye increases its outflow mantaining the homeostasis. Instead,
in glaucomatous eyes, the impaired trabecular outflow fails to maintain the hydrodynamic
equilibrium and IOP increases. Fluorophotometry proves that the D1 dopaminergic stimula‐
tion, induced by 2% ibopamine, undoubtedly increases the aqueous humor production.
Ibopamine, when instilled, prior to the Laminaria, into the healthy rabbit eyes does not
significantly affect the IOP, while in the eyes treated with Laminaria digitata induces ocular
hypertension.
3. Provocative test in glaucoma
Ibopamine 2% eye drops have a positive pressure effect in 50% of suspected normal-tension
glaucoma eyes and may differentiate between eyes with normal trabecular outflow capacity
and eyes with increased resistance in the trabecular meshwork that are ready to have pressure
peaks and deterioration to glaucoma [18].
A long-term treatment with corticosteroids can induce ocular hypertension. They increase the
IOP by interfering with the aqueous humor outflow system. By administering dexamethasone
at two different concentrations (0.1 and 1%) in eyes suffering from allergic conjunctivitis, the
ibopamine test was positive, in a dose-dependent manner, from 33 to 50%.
Ibopamine test is useful in detecting an impairment of the outflow system also in patients
affected by psudoexfoliative syndrome (PEX) [19]. This test is also positive when PEX syn‐
drome is unilateral. It exerts a significant additive effect on mydriasis of PEX eyes induced
with 10% phenylephrine-0.5% tropicamide with only minimal increase in IOP [20].
The ibopamine test is positive in 44.33% of offspring of one glaucoma parent without glau‐
comatous damage. It signifies an impaired function of the outflow structures and, therefore,
a predisposition to intraocular hypertension and possible glaucoma in some years [21,22].
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Ocular hypotony is a pathological condition of the IOP when it decreases to values below 6-7
mmHg. IOP values below 4 mmHg usually cause progressive damage to the eye [23]. Ocular
hypotony can be caused by a damage to ciliary body from trauma or inflammation. In the
treatment of ocular hypotony, ibopamine can be administerd every 3 hours or 3-4 times daily,
associated to corticosteroid therapy [24,25].
4. Conclusion
In conclusion, 2% ibopamine eye drops test is a useful pharmacological tool allowing us to
study the pathophysiology of hydrodynamic disorders and in evaluating the outflow impair‐
ment. It is useful as a therapeutic drug in ocular hypotony secondary to filtering surgery,
vitreo-retinal surgery or long-lasting uveitis. That's why its use is adviced in all the Ophthal‐
mological Department in EU and USA.
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